Pharmaceutical Technology

JUNE 15, 2023

By targeting exposed CLDN1 on cancer cells, our antibody remodels the extracellular matrix favouring T and NK-cell [natural killer cells] trafficking, which in turn directly kills CLDN1+ tumour cells and breaks the checkpoint inhibitor resistance in immune-excluded tumours.

FDA 52

FDA Immunization 52

European Pharmaceutical Review

JULY 25, 2022

For pharmaceutical manufacturers, the primary solution has long been to build anti-counterfeiting technology directly into medical packaging – providing a convenient method for tracking products across supply chains as well as visual authenticity for the consumer. But what exactly does this look like? . The first line of defence.

Packaging 86

Packaging 86

Hospital Pharmacy Europe

JULY 3, 2023

Most clinicians will be familiar with the use of the anti-inflammatory agent colchicine as a treatment for acute attacks of gout, which is surprising given the lack of good quality evidence for the drug. Rod Tucker considers the evidence and what this means for CVD management.

Hospitals 52

Hospitals FDA 52